Cytometry News and Research

RSS

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

COVIDome Explorer online portal launched to accelerate COVID-19 research on a global scale

To further accelerate COVID-19 research on a global scale, investigators from the University of Colorado Anschutz Medical Campus have created a multidimensional dataset, known as the COVIDome dataset, derived from hospitalized COVID-19 patients versus negative controls.

17 Aug 2021

Biotium releases new ExoBrite EV Membrane Staining Kits

Biotium, a leading supplier and inventor of fluorescent cellular probes for life science research, announces the release of new ExoBrite™ EV Membrane Staining Kits.

17 Aug 2021

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

A new study published in the journal Nature Communications has reported two neutralizing antibodies, namely, nCoVmab1 and nCoVmab2, which are potent against SARS-CoV-2.

13 Aug 2021

New insight into impact of SARS-CoV-2 mutations on receptor binding

A recent study by Canadian researchers, currently available on the bioRxiv* preprint server, contributes to the growing body of literature on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by appraising the impact of single mutations on their overall antigenicity and binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor.

9 Aug 2021

Long COVID may be due to persistent immune disturbances

A new study discusses abnormalities in the immune response following COVID-19 in samples collected from patients who have recovered from COVID-19.

8 Aug 2021

University of Pittsburgh invests in Canopy Biosciences’ ChipCytometry instrument for spatial biology

Canopy Biosciences, a Bruker Company, today announced that the University of Pittsburgh will add ChipCytometry for high-plex single-cell spatial biology to its capabilities at the Unified Flow Core in the Department of Immunology

From Bruker Nano Surfaces and Metrology 6 Aug 2021

New study examines B cell receptor repertoires in COVID-19 patients

In a paper recently uploaded to the preprint server bioRxiv* by Kim et al. (August 2, 2021), the B cell receptor repertoire of 1,060 COVID-19 patients is compared to that of an equal number of healthy volunteers in a novel manner, utilizing computational deep-learning-based protein embedding techniques, which demonstrate a resolution capable of tracking the changes in immunity in an individual over the course of infection.

5 Aug 2021

Drug combination could make curative surgery possible for some liver cancer patients

A combination of the kinase-inhibitor drug cabozantinib and the immunotherapy drug nivolumab can make curative surgery possible in some liver cancer patients who would normally not be considered surgery candidates.

29 Jul 2021

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

A study analyzes the immune responses of medical personnel, as well as immunocompromised DP and immunosuppressed KTR patients.

27 Jul 2021

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

PerkinElmer, Inc. today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents.

From Revvity 27 Jul 2021

Variations in human ACE2 genetics associated with coronavirus susceptibility

In a recent study, the researchers sought to understand the genetic variability in ACE2 that may contribute to inconsistent clinical outcomes of COVID-19.

25 Jul 2021

Research uncovers an unexpected role for immune T cells in protection against malaria

Advanced technologies have been used to solve a long-standing mystery about why some people develop serious illness when they are infected with the malaria parasite, while others carry the infection asymptomatically.

23 Jul 2021

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

RUDN University biologists discover the way how macrophages respond to inflammation

RUDN University biologists discovered the way how macrophages (the cells of the "first line" immune response) respond to inflammation and identified how the immune response depends on their origin.

16 Jul 2021

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.

16 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Researchers discover new set of signals that control production of goblet cells in the lung

Proper lung function relies on the precise balance of specialized epithelial cells (cells that line the surfaces of the body) that coordinate functions to maintain homeostasis.